Previous 10 | Next 10 |
-- Record Revenues of $42M; Increase of 49% over $28.2M in Fiscal 2021 -- -- Orders Increased 48% to $49.6M -- -- Increased Revenue Guidance for Fiscal 2022 -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of hi...
Twist Bioscience (NASDAQ:TWST) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open. The consensus EPS Estimate is -$1.06 (-47.2% Y/Y) and the consensus Revenue Estimate is $38.22M (+35.5% Y/Y). Over the last 1 year, TWST has beaten EPS estimates 75% of the...
Twist Bioscience (NASDAQ:TWST) and Abcam (NASDAQ:ABCM) have announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications. Under the terms of the agreement, Tw...
Abcam to license in VHH phage library (1) from Twist, complementing in-house recombinant antibody capabilities Abcam to develop and commercialize antibodies for diagnostic and research use, with Twist retaining rights for therapeutic applications Reinforces Abcam...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its inaugural environmental social and governance (ESG) report highlighting Twist’s approach to susta...
Don't think that the current malaise for biotech investors will last forever. There are some biotech stocks that have tremendous long-term potential. We asked three Motley Fool contributors to identify biotech stocks they think could deliver 5x returns by 2030. Here's why they chose C...
CRISPR Therapeutics (NASDAQ: CRSP) focuses on modifying DNA. Twist Bioscience (NASDAQ: TWST) focuses on making DNA. Both companies' technologies appear to have tremendous potential. But which is the better biotech stock to buy? That's the question that Motley Fool contributo...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Artisan Development Labs Inc. (DBA Artisan Bio), an immune cell engineering company developing next-generation cell the...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 first quarter ended December 31, 2021, before ...
The beating that life science stocks have taken lately is enough to make most investors think twice before risking another hard-earned dollar in this topsy-turvey corner of the stock market. If you can detach your emotions from your math skills, though, you know that there's no better time ...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...